(NASDAQ: ALXO) Alx Oncology Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Alx Oncology Holdings's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ALXO's revenue for 2027 to be $3,124,337,409, with the lowest ALXO revenue forecast at $3,124,337,409, and the highest ALXO revenue forecast at $3,124,337,409. On average, 1 Wall Street analysts forecast ALXO's revenue for 2028 to be $7,455,975,230, with the lowest ALXO revenue forecast at $7,455,975,230, and the highest ALXO revenue forecast at $7,455,975,230.
In 2029, ALXO is forecast to generate $798,453,659 in revenue, with the lowest revenue forecast at $798,453,659 and the highest revenue forecast at $798,453,659.